MC
Highly rated in
10
conditions

Dr. Merit E. Cudkowicz

Partners TeleStroke Center
Boston, MA
Highly rated in
10
conditions
Specialties:Neurology
Experience:33 Years
Clinical Trials:Currently Recruiting for 2 Trials
Accepts:New PatientsMedicare
Highly rated in
10
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Merit E. Cudkowicz's experience treating your condition:
About Dr. Merit E. Cudkowicz

Merit Cudkowicz is a Neurologist in Boston, Massachusetts. Cudkowicz has been practicing medicine for over 33 years and is highly rated in 10 conditions, according to our data. Her top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Parkinson's Disease, and Dementia. She is licensed to treat patients in Massachusetts. Cudkowicz is currently accepting new patients.

Her clinical research consists of co-authoring 198 peer reviewed articles and participating in 21 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Merit E. Cudkowicz it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Merit E. Cudkowicz accepts the following insurance:

  •  Ambetter
  •  Anthem
Locations
15 Parkman St, Wacc 729j, Boston, MA 02114
Other Locations
165 Cambridge St, Boston, MA 02114
Background & Education
Graduate Institution
Harvard Medical School, 1990
Specialties
Neurology
Licenses
Psychiatry & Neurology in MA
Hospital Affiliations
Parkland Medical Center
Massachusetts General Hospital
Newton-Wellesley Hospital
Languages Spoken
English
Italian
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials
HEALEY ALS Platform Trial
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug
Study Drugs: ZilucoplanVerdiperstatCNM-Au8Pridopidine
Study Phase: Phase 2/Phase 3
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
Enrollment Status: Recruiting
Publish Date: September 21, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Terminated
Publish Date: April 19, 2011
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
An Open-Label, Safety and Tolerability, Study Evaluating KNS-760704 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Completed
Publish Date: August 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease
Enrollment Status: Completed
Publish Date: April 19, 2013
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Phase II/III Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Completed
Publish Date: January 11, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: June 07, 2021
Intervention Type: Drug
Study Phase: Phase 3
Coenzyme Q10 in Huntington's Disease (HD)
Enrollment Status: Terminated
Publish Date: March 30, 2016
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)
Enrollment Status: Completed
Publish Date: April 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Enrollment Status: Completed
Publish Date: July 18, 2018
Intervention Type: Biological
Study Phase: Phase 2
An Intermediate Expanded Access Protocol for Amyotrophic Lateral Sclerosis With CNM-Au8
Enrollment Status: Available
Publish Date: March 11, 2022
Intervention Type: Drug
HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose
Enrollment Status: Enrolling by invitation
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drug: SLS-005
Study Phase: Phase 2/Phase 3
HEALEY ALS Platform Trial - Regimen D Pridopidine
Enrollment Status: Active, not recruiting
Publish Date: September 21, 2022
Intervention Type: Drug
Study Drug: Pridopidine
Study Phase: Phase 2/Phase 3
A Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Withdrawn
Publish Date: February 09, 2012
Intervention Type: Drug
Study Phase: Phase 2
Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Completed
Publish Date: April 21, 2014
Intervention Type: Other, Drug
Study Phase: Phase 3
The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Completed
Publish Date: March 24, 2017
Intervention Type: Drug
Study Phase: Phase 2
HEALEY ALS Platform Trial - Regimen A Zilucoplan
Enrollment Status: Active, not recruiting
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drug: Zilucoplan
Study Phase: Phase 2/Phase 3
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Completed
Publish Date: February 09, 2012
Intervention Type: Drug
Study Phase: Phase 2
HEALEY ALS Platform Trial - Regimen C CNM-Au8
Enrollment Status: Active, not recruiting
Publish Date: June 30, 2022
Intervention Type: Drug
Study Drug: CNM-Au8
Study Phase: Phase 2/Phase 3
HEALEY ALS Platform Trial - Regimen B Verdiperstat
Enrollment Status: Active, not recruiting
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drug: Verdiperstat
Study Phase: Phase 2/Phase 3
View 19 Less Clinical Trials -
197 Total Publications
Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A Review.
Journal: JAMA neurology
Published: October 17, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
SP
Dr. Scott R. Plotkin
Neurology
Highly rated in
33
conditions
Neurology

Mass General Brigham

Pappas Center For Neuro Oncology

55 Fruit St, 
Boston, MA 
 0.1 mi

Scott Plotkin is a Neurologist in Boston, Massachusetts. Plotkin has been practicing medicine for over 25 years and is highly rated in 33 conditions, according to our data. His top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Acoustic Neuroma, and Gamma Knife Radiosurgery. He is licensed to treat patients in Massachusetts. Plotkin is currently accepting new patients.

PW
Dr. Patrick Y. Wen
Neurology
Highly rated in
26
conditions
Neurology

Dana Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 2.7 mi

Patrick Wen is a Neurologist in Boston, Massachusetts. Wen has been practicing medicine for over 42 years and is highly rated in 26 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Gamma Knife Radiosurgery. He is licensed to treat patients in Massachusetts. Wen is currently accepting new patients.

JS
Dr. Jeremy D. Schmahmann
Neurology
Highly rated in
52
conditions
Neurology

Mass General Brigham

Massachusetts General Physicians Organization Inc

55 Fruit Street, 
Boston, MA 
 0.1 mi

Jeremy Schmahmann is a Neurologist in Boston, Massachusetts. Schmahmann has been practicing medicine for over 43 years and is highly rated in 52 conditions, according to our data. His top areas of expertise are Acute Cerebellar Ataxia, Spinocerebellar Ataxia, Olivopontocerebellar Atrophy, and Drug Induced Dyskinesia. He is licensed to treat patients in Massachusetts. Schmahmann is currently accepting new patients.